Opioid Withdrawal Clinical Trial
Official title:
Lofexidine for Rapid Pre-Operative Opioid Tapering in Adults Undergoing Lumbar Spine Surgery
Verified date | January 2022 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective is to investigate the effects of lofexidine in adults undergoing opioid tapering prior to elective lumbar spine surgery.
Status | Completed |
Enrollment | 6 |
Est. completion date | April 15, 2021 |
Est. primary completion date | April 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Age 18 to 70 years. 2. Chronic lumbar spine pain for = 3 months duration. 3. Scheduled for elective lumbar spine surgery. 4. Daily morphine equivalent dose between 50 mg and 200 mg. Exclusion Criteria: 1. Cancer-related pain. 2. Medical or surgical conditions that could be adversely impacted by opioid tapering or use of lofexidine including, but not exclusively limited to, cardiac disease, inflammatory bowel disease, renal or hepatic impairment, vascular disease, and history of anaphylaxis. Patients may be excluded for other comorbid medical or surgical conditions based on the physician investigator's discretion. 3. History of schizophrenia or other chronic psychiatric disorder that could be adversely impacted by opioid tapering or use of lofexidine. Patients may be excluded for other comorbid mental health conditions based on the physician investigator's discretion. 4. Neurological condition that impair functioning in an ambulatory setting or could be adversely impacted by opioid tapering or use of lofexidine including, but not exclusively limited to, Parkinson's disease, amyotrophic lateral sclerosis, or a dementing illness. Patients may be excluded for other neurological conditions based on the physician investigator's discretion. 5. Active substance abuse disorder. 6. Inability to function in an ambulatory care setting due to severe deconditioning requiring use of supportive gait aids including a cane or walker. Patients may be excluded for other functional problems based on the physician investigator's discretion. 7. History of adverse effects attributed to opioid tapering or lofexidine use. 8. Use of medications from drug classes known to have adverse interactions with lofexidine including, but not exclusively limited to, beta-blockers, calcium channel blockers, alpha 1 and 2 receptor antagonists, tricyclic antidepressants, benzodiazepines, and selective serotonin reuptake inhibitors. Patients may be excluded for use of other medications based on the physician investigator's and research pharmacy's discretion. |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | USWM, LLC (dba US WorldMeds) |
United States,
Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW; CLEEN-SLATE Team. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict Med. 2019 May/Jun;13(3):169-176. doi: 10.1097/ADM.0000000000000474. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Opioid Tapering | The number of patients who achieve a 50% reduction in daily opioid dose at day 12. | 12 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Completed |
NCT04140955 -
Opioid Tapering After Spine Surgery
|
N/A | |
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
Completed |
NCT01262092 -
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
|
Phase 2 | |
Completed |
NCT04075214 -
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
|
N/A | |
Recruiting |
NCT04325659 -
An Innovative Intervention for OUD Treatment
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03678792 -
Comparison of Three Opioid Detoxification Treatment Regimens
|
Phase 3 | |
Terminated |
NCT04162145 -
BRIDGE Device for Treatment of Opioid Withdrawal
|
N/A | |
Completed |
NCT04238754 -
Oral Cannabidiol for Opioid Withdrawal
|
Phase 1/Phase 2 | |
Recruiting |
NCT05053503 -
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
|
N/A | |
Recruiting |
NCT05555485 -
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
|
N/A | |
Active, not recruiting |
NCT03485430 -
Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up
|
N/A | |
Recruiting |
NCT05790551 -
Suboxone Dispenser for OUD
|
N/A | |
Completed |
NCT03174067 -
Buprenorphine in the Emergency Department
|
Phase 4 | |
Completed |
NCT04731935 -
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
|
N/A | |
Completed |
NCT04470050 -
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06442566 -
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT05307458 -
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
|
||
Completed |
NCT03789214 -
Medical Management of Sleep Disturbance During Opioid Tapering
|
Phase 2 | |
Recruiting |
NCT04759703 -
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
|
Phase 2/Phase 3 |